Graça Cardoso1, Joao Graca2, Catarina Klut2, Bruno Trancas2, Ana Papoila3. 1. a CEDOC and Mental Health Department, NOVA Medical School/Faculdade de Ciências Médicas , Universidade Nova de Lisboa , Lisboa , Portugal. 2. b Department of Psychiatry , Hospital Fernando Fonseca , Amadora Portugal. 3. c CEAUL, NOVA Medical School/Faculdade de Ciências Médicas , Universidade Nova de Lisboa , Lisboa , Portugal.
Abstract
INTRODUCTION: The aims of the present study were to assess demographic and clinical characteristics of patients after receiving a cancer diagnosis, and to determine possible risk factors for anxiety and depression. METHODS: All consecutive patients aged 18 or above, were assessed before starting intravenous chemotherapy for the first time with the Hospital Anxiety and Depression Scale (HADS), the Distress Thermometer, and a Visual Analog Scale for pain. Demographic and clinical data were also collected. RESULTS: The patients assessed (n = 270) had a mean age of 59.4 (SD = 11.8) years, and 50.7% were women. Tumours were more frequently colorectal (27.2%), lung (18.8%) and breast (17.6%), and 68.9% were stages 3 or 4. A HADS Anxiety score ≥8 was present in 30% of the patients, a Depression score ≥8 in 24.1%, and a Distress score ≥4 in 44.4%. Independent risk factors for HADS Depression score ≥8 were being a woman (OR = 2.45; p = 0.004), being older (OR = 1.04; p = 0.005), and cancer stage 3-4 (OR = 2.24; p = 0.023) in the multivariable analysis; for Anxiety ≥8 they were being a woman (OR = 2.47; p = 0.002), having a past psychiatric consultation (OR = 2.83; p = 0.029), and cancer stage 3-4 (OR = 1.90; p = 0.047). CONCLUSION: These results suggest the need for greater awareness and a differentiated approach to patients at increased risk of anxiety and depression in the early stages of treatment and before starting chemotherapy.
INTRODUCTION: The aims of the present study were to assess demographic and clinical characteristics of patients after receiving a cancer diagnosis, and to determine possible risk factors for anxiety and depression. METHODS: All consecutive patients aged 18 or above, were assessed before starting intravenous chemotherapy for the first time with the Hospital Anxiety and Depression Scale (HADS), the Distress Thermometer, and a Visual Analog Scale for pain. Demographic and clinical data were also collected. RESULTS: The patients assessed (n = 270) had a mean age of 59.4 (SD = 11.8) years, and 50.7% were women. Tumours were more frequently colorectal (27.2%), lung (18.8%) and breast (17.6%), and 68.9% were stages 3 or 4. A HADS Anxiety score ≥8 was present in 30% of the patients, a Depression score ≥8 in 24.1%, and a Distress score ≥4 in 44.4%. Independent risk factors for HADS Depression score ≥8 were being a woman (OR = 2.45; p = 0.004), being older (OR = 1.04; p = 0.005), and cancer stage 3-4 (OR = 2.24; p = 0.023) in the multivariable analysis; for Anxiety ≥8 they were being a woman (OR = 2.47; p = 0.002), having a past psychiatric consultation (OR = 2.83; p = 0.029), and cancer stage 3-4 (OR = 1.90; p = 0.047). CONCLUSION: These results suggest the need for greater awareness and a differentiated approach to patients at increased risk of anxiety and depression in the early stages of treatment and before starting chemotherapy.
Authors: Deblina Dey; Vipan K Parihar; Gergely G Szabo; Peter M Klein; Jenny Tran; Jonathan Moayyad; Faizy Ahmed; Quynh-Anh Nguyen; Alexandria Murry; David Merriott; Brandon Nguyen; Jodi Goldman; Maria C Angulo; Daniele Piomelli; Ivan Soltesz; Janet E Baulch; Charles L Limoli Journal: Radiat Res Date: 2020-03-05 Impact factor: 2.841
Authors: Luana La Marca; Erika Maniscalco; Francesco Fabbiano; Francesco Verderame; Adriano Schimmenti Journal: Support Care Cancer Date: 2018-08-29 Impact factor: 3.603
Authors: Efi Parpa; Eleni Tsilika; Antonis Galanos; Maria Nikoloudi; Kyriaki Mystakidou Journal: Support Care Cancer Date: 2019-03-21 Impact factor: 3.603
Authors: Simon J Craddock Lee; Mark A Clark; John V Cox; Burton M Needles; Carole Seigel; Bijal A Balasubramanian Journal: J Oncol Pract Date: 2016-10-31 Impact factor: 3.840
Authors: Heide Götze; Michael Friedrich; Elmar Brähler; Georg Romer; Anja Mehnert; Jochen Ernst Journal: Support Care Cancer Date: 2016-09-13 Impact factor: 3.603
Authors: Jamie M Jacobs; Molly E Ream; Nicole Pensak; Lauren E Nisotel; Joel N Fishbein; James J MacDonald; Joanne Buzaglo; Inga T Lennes; Steven A Safren; William F Pirl; Jennifer S Temel; Joseph A Greer Journal: J Natl Compr Canc Netw Date: 2019-03-01 Impact factor: 11.908